Enanta Pharmaceuticals, Inc. (ENTA)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
13.60 USD
-0.20
(-1.449%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.60 |
Hot Take ↕ | Aug. 22, 2026, 5:56 a.m. EDT
The investment case here is fractured by a stark divergence between optimistic analyst targets and deteriorating business reality. While analysts see a path to $28, the company's fundamentals tell a different story: revenue has contracted by 21.6%, profitability is deeply negative with operating margins at -120%, and the stock has suffered a brutal 62.76% cumulative decline over the last nine years. Crucially, the price action confirms this structural deterioration, as the stock has endured three consecutive years of negative annual returns, a pattern that typically signals a failing business model rather than a temporary setback. With no dividend to provide income and a balance sheet showing negative free cash flow, the stock offers no safety margin. The recent price bounce appears to be a technical relief rally rather than a reversal of the long-term downtrend, leaving investors exposed to the risk of further value destruction. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.029960 |
| AutoETS | 0.152347 |
| AutoTheta | 0.163097 |
| MSTL | 0.233721 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 0.82 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.696 |
| Excess Kurtosis | -0.58 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 180.116 |
| Revenue per Share | 2.411 |
| Market Cap | 396,105,472 |
| Forward P/E | -5.38 |
| Beta | 0.93 |
| Profit Margins | -96.89% |
| Website | https://www.enanta.com |
As of Aug. 22, 2026, 5:56 a.m. EDT: Speculators are positioning for continued volatility rather than a directional breakout. Call open interest is heavily skewed out-of-the-money (OTM) at strikes like $15.00 and $17.50, suggesting bets on a rally to $20+, while put open interest concentrates at lower strikes ($10.00, $12.50), indicating a floor or hedging against further downside. The heavy OTM bias in both calls and puts implies a 'long gamma' environment where the market expects significant swings but lacks a clear consensus on which way the price will break immediately.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5333333 |
| Address1 | 4 Kingsbury Avenue |
| All Time High | 127.77 |
| All Time Low | 4.09 |
| Ask | 17.24 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 260,310 |
| Average Daily Volume3 Month | 214,720 |
| Average Volume | 214,720 |
| Average Volume10Days | 260,310 |
| Beta | 0.931 |
| Bid | 13.62 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 3.471 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.6 |
| Current Ratio | 3.759 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 13.91 |
| Day Low | 13.48 |
| Debt To Equity | 180.116 |
| Display Name | Enanta Pharmaceuticals |
| Earnings Call Timestamp End | 1,715,027,400 |
| Earnings Call Timestamp Start | 1,715,027,400 |
| Earnings Timestamp End | 1,794,859,200 |
| Earnings Timestamp Start | 1,794,859,200 |
| Ebitda | -53,819,000 |
| Ebitda Margins | -0.82471 |
| Enterprise To Ebitda | -7.221 |
| Enterprise To Revenue | 5.955 |
| Enterprise Value | 388,639,456 |
| Eps Current Year | -2.36 |
| Eps Forward | -2.53 |
| Eps Trailing Twelve Months | -2.39 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 617 607 0530 |
| Fifty Day Average | 13.523 |
| Fifty Day Average Change | 0.07700062 |
| Fifty Day Average Change Percent | 0.0056940485 |
| Fifty Two Week Change Percent | 53.33333 |
| Fifty Two Week High | 17.15 |
| Fifty Two Week High Change | -3.5499992 |
| Fifty Two Week High Change Percent | -0.20699705 |
| Fifty Two Week Low | 7.05 |
| Fifty Two Week Low Change | 6.55 |
| Fifty Two Week Low Change Percent | 0.92907804 |
| Fifty Two Week Range | 7.05 - 17.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,363,872,600,000 |
| Float Shares | 22,513,062 |
| Forward Eps | -2.53 |
| Forward P E | -5.3754945 |
| Free Cashflow | -22,656,876 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 120 |
| Fullday Change | -0.2 |
| Fullday Change Percent | -1.44927 |
| Fullday Price | 13.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 1.0 |
| Gross Profits | 65,258,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04671 |
| Held Percent Institutions | 0.94332004 |
| Implied Shares Outstanding | 29,125,402 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Long Business Summary | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts. |
| Long Name | Enanta Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 396,105,472 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_345286 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -63,230,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 401,930,547 |
| Number Of Analyst Opinions | 5 |
| Open | 13.91 |
| Operating Cashflow | -35,316,000 |
| Operating Margins | -1.2003601 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 617 607 0800 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.6 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 13.8 |
| Price Eps Current Year | -5.7627125 |
| Price Hint | 2 |
| Price To Book | 3.9181793 |
| Price To Sales Trailing12 Months | 6.0698376 |
| Profit Margins | -0.96892 |
| Quick Ratio | 3.619 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.2 |
| Region | US |
| Regular Market Change | -0.2 |
| Regular Market Change Percent | -1.44927 |
| Regular Market Day High | 13.91 |
| Regular Market Day Low | 13.48 |
| Regular Market Day Range | 13.48 - 13.91 |
| Regular Market Open | 13.91 |
| Regular Market Previous Close | 13.8 |
| Regular Market Price | 13.6 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 155,913 |
| Return On Assets | -0.122779995 |
| Return On Equity | -0.7012 |
| Revenue Growth | -0.216 |
| Revenue Per Share | 2.411 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,125,402 |
| Shares Percent Shares Out | 0.092 |
| Shares Short | 2,679,755 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,441,185 |
| Short Name | Enanta Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1101 |
| Short Ratio | 16.74 |
| Source Interval | 15 |
| State | MA |
| Symbol | ENTA |
| Target High Price | 20.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 19.8 |
| Target Median Price | 20.0 |
| Total Cash | 189,506,000 |
| Total Cash Per Share | 6.507 |
| Total Debt | 182,040,000 |
| Total Revenue | 65,258,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.39 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 13.5573 |
| Two Hundred Day Average Change | 0.042700768 |
| Two Hundred Day Average Change Percent | 0.0031496515 |
| Type Disp | Equity |
| Volume | 155,913 |
| Website | https://www.enanta.com |
| Zip | 2,472 |